United States - English - NLM (National Library of Medicine)

sanum kehlbeck gmbh & co. kg - streptococcus pneumoniae immunoserum rabbit (unii: iwj46h2h5c) (streptococcus pneumoniae immunoserum rabbit - unii:iwj46h2h5c), staphylococcus aureus immunoserum rabbit (unii: q1g8tgq05j) (staphylococcus aureus immunoserum rabbit - unii:q1g8tgq05j) - streptococcus pneumoniae immunoserum rabbit 9 [hp_x] in 10 ml - homeopathic medicine 0.34 fl oz (10 ml) for minor focal oral infections.

Malta - English - Medicines Authority

bruschettini s.r.l. via isonzo 6 - 16147 genova, italy - branhamella catarrhalis, haemophilus influenzae, klebsiella pneumoniae, streptococcus pyogenes, staphylococcus aureus, streptococcus pneumoniae - oral drops, suspension - streptococcus pyogenes 126.2 agu/ml branhamella catarrhalis 39.9 agu/ml staphylococcus aureus 79.6 agu/ml haemophilus influenzae b 50.2 agu/ml klebsiella pneumoniae 39.8 agu/ml streptococcus pneumoniae 63.2 agu/ml - vaccines

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - staphylococcus aureus (unii: o478wx4004) (staphylococcus aureus - unii:o478wx4004), klebsiella pneumoniae (unii: 09pa36ct5r) (klebsiella pneumoniae - unii:09pa36ct5r), enterococcus faecalis (unii: 15e04lz9ct) (enterococcus faecalis - unii:15e04lz9ct), streptococcus pneumoniae (unii: bt6u234yr2) (streptococcus pneumoniae - unii:bt6u234yr2), streptococcus agalactiae (unii: 2b3763s671) (streptococcus agalactiae - unii:2b3763s671), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j3 - staphylococcus aureus 15 [hp_x] in 1 ml - for temporary relief of symptoms related to upper respiratory infections including fever, irritated throat, swollen glands, inflamed sinus, cough and runny nose.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to upper respiratory infections including fever, irritated throat, swollen glands, inflamed sinus, cough and runny nose.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - staphylococcus aureus (unii: o478wx4004) (staphylococcus aureus - unii:o478wx4004), klebsiella pneumoniae (unii: 09pa36ct5r) (klebsiella pneumoniae - unii:09pa36ct5r), enterococcus faecalis (unii: 15e04lz9ct) (enterococcus faecalis - unii:15e04lz9ct), streptococcus pneumoniae (unii: bt6u234yr2) (streptococcus pneumoniae - unii:bt6u234yr2), streptococcus agalactiae (unii: 2b3763s671) (streptococcus agalactiae - unii:2b3763s671), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j3 - staphylococcus aureus 15 [hp_x] in 1 ml - for temporary relief of symptoms related to upper respiratory infections including fever, swollen glands, inflamed sinus, cough and runny nose.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to upper respiratory infections including fever, swollen glands, inflamed sinus, cough and runny nose.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - staphylococcus aureus (unii: o478wx4004) (staphylococcus aureus - unii:o478wx4004), klebsiella pneumoniae (unii: 09pa36ct5r) (klebsiella pneumoniae - unii:09pa36ct5r), enterococcus faecalis (unii: 15e04lz9ct) (enterococcus faecalis - unii:15e04lz9ct), streptococcus pneumoniae (unii: bt6u234yr2) (streptococcus pneumoniae - unii:bt6u234yr2), streptococcus agalactiae (unii: 2b3763s671) (streptococcus agalactiae - unii:2b3763s671), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j3 - staphylococcus aureus 15 [hp_x] - for temporary relief of symptoms related to upper respiratory infections including fever, cough and runny nose.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to upper respiratory infections including fever, cough and runny nose.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - staphylococcus aureus (unii: o478wx4004) (staphylococcus aureus - unii:o478wx4004), klebsiella pneumoniae (unii: 09pa36ct5r) (klebsiella pneumoniae - unii:09pa36ct5r), enterococcus faecalis (unii: 15e04lz9ct) (enterococcus faecalis - unii:15e04lz9ct), streptococcus pneumoniae (unii: bt6u234yr2) (streptococcus pneumoniae - unii:bt6u234yr2), streptococcus agalactiae (unii: 2b3763s671) (streptococcus agalactiae - unii:2b3763s671), streptococcus mutans (unii: 5c7j33mjj1) (streptococcus mutans - unii:5c7j33mjj1), haemophilus influenzae type b (unii: f2tw0n64fi) (haemophilus influenzae type b - unii:f2tw0n64fi), streptococcus viridans group (unii: nnv2379hkr) (streptococcus viridans group - unii:nnv2379hkr) - staphylococcus aureus 15 [hp_x] in 1 ml - for temporary relief of symptoms related to upper respiratory infections including fever, cough and runny nose.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to upper respiratory infections including fever, cough and runny nose.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg); amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate type a; dichloromethane; isopropyl alcohol; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - clavam tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to clavam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to clavam tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 1004.31 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; sodium starch glycollate; dichloromethane; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amoxyclav b&b 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis.,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infections.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.